{"doi":"10.1111/josh.13262","title":"<scp>COVID</scp>‐19‐Related Facilitators and Barriers to <scp>In‐Person</scp> Learning for Children With Intellectual and Development Disabilities","abstract":"BACKGROUND: Schools provide essential functions for children with intellectual and developmental disabilities (IDD), but their vulnerability to infection with SARS-CoV-2 are a barrier to in-person learning. This qualitative study aimed to understand how weekly SARS-CoV-2 screening testing of students and staff could best facilitate in-school learning during the pandemic. METHODS: Thirty-one focus groups were held with school staff and parents of children with IDD to examine the perceptions of COVID-19 during the 2020-2021 school year. Responses were analyzed using a directed thematic content analysis approach. RESULTS: Five principal themes were identified: risks of returning to in-person learning; facilitators and barriers to participation in SARS-CoV-2 screening testing; messaging strategies; and preferred messengers. IMPLICATIONS FOR SCHOOL HEALTH POLICY, PRACTICE, AND EQUITY: Staff and families agreed that saliva-based SARS-CoV-2 screening testing helps increase comfort with in-person learning. Screening testing increased family and school staff comfort with in-person learning particularly because many students with special needs cannot adhere to public health guidelines. CONCLUSION: To keep children with IDD in school during the pandemic, families found SARS-CoV-2 screening testing important, particularly for students that cannot adhere to mitigation guidelines.","journal":"Journal of School Health","year":2022,"id":284271,"datarank":0.40294980905215827,"base_score":1.9459101490553132,"endowment":1.9459101490553132,"self_citation_contribution":0.29188652235829704,"citation_network_contribution":0.11106328669386124,"self_endowment_contribution":0.29188652235829704,"citer_contribution":0.11106328669386124,"corpus_percentile":null,"corpus_rank":null,"citation_count":6,"citer_count":3,"citers_with_citation_signal":2,"citers_with_endowment":2,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9472,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT04565509"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":244582,"name":"Ann Marie Schmidt","orcid":"0000-0001-8902-070X","position":1,"is_corresponding":false},{"id":756719,"name":"Nikole Lobb Dougherty","orcid":null,"position":2,"is_corresponding":false},{"id":756049,"name":"Michael R. Sherby","orcid":"0000-0003-1941-2550","position":3,"is_corresponding":false},{"id":756053,"name":"Jason G. Newland","orcid":"0000-0003-1060-0344","position":4,"is_corresponding":false},{"id":756724,"name":"Nancy B. Mueller","orcid":null,"position":5,"is_corresponding":false},{"id":962008,"name":"for the COMPASS‐T Study Group","orcid":null,"position":6,"is_corresponding":false},{"id":756055,"name":"Liz E. Vestal","orcid":"0000-0002-3441-8929","position":0,"is_corresponding":true}],"reference_count":31,"raw_metadata":null,"created_at":"2026-07-19T00:29:32.702533Z","pmid":"36404403","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}